Search Results - "McArthur, A."

The Cell-Cycle Regulator CDK4: An Emerging Therapeutic Target in Melanoma by SHEPPARD, Karen E, MCARTHUR, Grant A

“…The recent clinical success of targeted therapies in melanoma directed at the oncogene BRAF validates the concept of targeting oncogenes. The p16-cyclin…”
Get full text

Combination Immune Checkpoint Inhibition: Is First Line Best? by McArthur, Grant A

Get full text

Targeting Oncogenic Drivers and the Immune System in Melanoma by MCARTHUR, Grant A, RIBAS, Antoni

“…Melanoma is one of the most common cancers in Western countries but has defied the trend of reductions in age-adjusted mortality observed in most other cancers…”
Get full text

Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual by Gershenwald, Jeffrey E., Scolyer, Richard A., Hess, Kenneth R., Sondak, Vernon K., Long, Georgina V., Ross, Merrick I., Lazar, Alexander J., Faries, Mark B., Kirkwood, John M., McArthur, Grant A., Haydu, Lauren E., Eggermont, Alexander M. M., Flaherty, Keith T., Balch, Charles M., Thompson, John F., Gershenwald, Jeffrey E., Scolyer, Richard A., Atkins, Michael B., Balch, Charles M., Barnhill, Raymond L., Bilimoria, Karl Y., Buzaid, Antonio C., Byrd, David R., Cochran, Alistair J., Eggermont, Alexander M. M., Elder, David E., Faries, Mark B., Flaherty, Keith T., Garbe, Claus, Gardner, Julie M., Gimotty, Phyllis A., Halpern, Allan C., Haydu, Lauren E., Hess, Kenneth R., Johnson, Timothy M., Kirkwood, John M., Lazar, Alexander J., Lee, Anne W. M., Long, Georgina V., McArthur, Grant A., Mihm Jr, Martin C., Prieto, Victor G., Ross, Merrick I., Sober, Arthur J., Sondak, Vernon K., Thompson, John F., Wong, Sandra L., Delman, Keith A., Santinami, Mario, Maurichi, Andrea, Nagore, Eduardo, Faries, Mark B., Thompson, John F., Scolyer, Richard A., McArthur, Grant A., Gyorki, David E., Henderson, Michael, Stratigos, Alexander J., Gogas, Helen, Gershenwald, Jeffrey E., Haydu, Lauren E., Rossi, Carlo Riccardo, Sommariva, Antonio

“…Answer questions and earn CME/CNE To update the melanoma staging system of the American Joint Committee on Cancer (AJCC) a large database was assembled…”
Get full text

Inhibition of RNA Polymerase I as a Therapeutic Strategy to Promote Cancer-Specific Activation of p53 by Bywater, Megan J., Poortinga, Gretchen, Sanij, Elaine, Hein, Nadine, Peck, Abigail, Cullinane, Carleen, Wall, Meaghan, Cluse, Leonie, Drygin, Denis, Anderes, Kenna, Huser, Nanni, Proffitt, Chris, Bliesath, Joshua, Haddach, Mustapha, Schwaebe, Michael K., Ryckman, David M., Rice, William G., Schmitt, Clemens, Lowe, Scott W., Johnstone, Ricky W., Pearson, Richard B., McArthur, Grant A., Hannan, Ross D.

“…Increased transcription of ribosomal RNA genes (rDNA) by RNA Polymerase I is a common feature of human cancer, but whether it is required for the malignant…”
Get full text

Dysregulation of the basal RNA polymerase transcription apparatus in cancer by Bywater, Megan J., Pearson, Richard B., McArthur, Grant A., Hannan, Ross D.

“…Key Points The core RNA polymerase (Pol) subunits and general transcription factors (GTFs) are rarely mutated in cancer, although some GTFs are consistently…”
Get full text

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma by Flaherty, Keith T, Puzanov, Igor, Kim, Kevin B, Ribas, Antoni, McArthur, Grant A, Sosman, Jeffrey A, O'Dwyer, Peter J, Lee, Richard J, Grippo, Joseph F, Nolop, Keith, Chapman, Paul B

“…Many melanomas contain an activating mutation in BRAF: a substitution of glutamic acid for valine at amino acid 600 (the V600E mutation). The authors conducted…”
Get full text

A Multi-Timescale Map of Radiative and Nonradiative Decay Pathways for Excitons in CdSe Quantum Dots by Knowles, Kathryn E, McArthur, Eric A, Weiss, Emily A

“…A combination of transient absorption (TA) and time-resolved photoluminescence (TRPL) spectroscopies performed on solution-phase samples of colloidal CdSe…”
Get full text

Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma by RIBAS, Antoni, KEFFORD, Richard, LORIGAN, Paul, KENDRA, Kari L, MAIO, Michele, TREFZER, Uwe, SMYLIE, Michael, MCARTHUR, Grant A, DRENO, Brigitte, NATHAN, Paul D, MACKIEWICZ, Jacek, KIRKWOOD, John M, MARSHALL, Margaret A, GOMEZ-NAVARRO, Jesus, BO HUANG, PAVLOV, Dmitri, HAUSCHILD, Axel, PUNT, Cornelis J. A, HAANEN, John B, MARMOL, Maribel, GARBE, Claus, GOGAS, Helen, SCHACHTER, Jacob, LINETTE, Gerald

“…In phase I/II trials, the cytotoxic T lymphocyte-associated antigen-4-blocking monoclonal antibody tremelimumab induced durable responses in a subset of…”
Get full text

Synthesis and characterization of 3D Ni nanoparticle/carbon nanotube cathodes for hydrogen evolution in alkaline electrolyte by McArthur, M.A., Jorge, L., Coulombe, S., Omanovic, S.

“…Renewable alternative energy sources are required to decrease or eliminate the use of environmentally unfriendly fossil fuels. Hydrogen produced by…”
Get full text

Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF -Mutant Melanoma by Delord, Jean-Pierre, Robert, Caroline, Nyakas, Marta, McArthur, Grant A, Kudchakar, Ragini, Mahipal, Amit, Yamada, Yasuhide, Sullivan, Ryan, Arance, Ana, Kefford, Richard F, Carlino, Matteo S, Hidalgo, Manuel, Gomez-Roca, Carlos, Michel, Daniela, Seroutou, Abdelkader, Aslanis, Vassilios, Caponigro, Giordano, Stuart, Darrin D, Moutouh-de Parseval, Laure, Demuth, Tim, Dummer, Reinhard

“…Encorafenib, a selective BRAF inhibitor (BRAFi), has a pharmacologic profile that is distinct from that of other clinically active BRAFis. We evaluated…”
Get full text

UV-Associated Mutations Underlie the Etiology of MCV-Negative Merkel Cell Carcinomas by Wong, Stephen Q, Waldeck, Kelly, Vergara, Ismael A, Schröder, Jan, Madore, Jason, Wilmott, James S, Colebatch, Andrew J, De Paoli-Iseppi, Ricardo, Li, Jason, Lupat, Richard, Semple, Timothy, Arnau, Gisela Mir, Fellowes, Andrew, Leonard, J Helen, Hruby, George, Mann, Graham J, Thompson, John F, Cullinane, Carleen, Johnston, Meredith, Shackleton, Mark, Sandhu, Shahneen, Bowtell, David D L, Johnstone, Ricky W, Fox, Stephen B, McArthur, Grant A, Papenfuss, Anthony T, Scolyer, Richard A, Gill, Anthony J, Hicks, Rodney J, Tothill, Richard W

“…Merkel cell carcinoma (MCC) is an uncommon, but highly malignant, cutaneous tumor. Merkel cell polyoma virus (MCV) has been implicated in a majority of MCC…”
Get full text

The Advantages and Challenges of Using FDG PET/CT for Response Assessment in Melanoma in the Era of Targeted Agents and Immunotherapy by Wong, Annie N. M., McArthur, Grant A., Hofman, Michael S., Hicks, Rodney J.

“…The treatment of melanoma has been revolutionised in recent years by advances in the understanding of the genomic landscape of this disease, which has led to…”
Get full text

Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic BRAF-Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor by KIM, Kevin B, KEFFORD, Richard, GONZALEZ, Rene, OTT, Patrick A, LONG, Georgina V, GARDNER, Olivia S, OUELLET, Daniele, YANMEI XU, DEMARINI, Douglas J, LE, Ngocdiep T, PATEL, Kiran, LEWIS, Karl D, PAVLICK, Anna C, INFANTE, Jeffrey R, RIBAS, Antoni, SOSMAN, Jeffrey A, FECHER, Leslie A, MILLWARD, Michael, MCARTHUR, GrantA, HWU, Patrick

“…BRAF mutations promote melanoma cell proliferation and survival primarily through activation of MEK. The purpose of this study was to determine the response…”
Get full text

Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study by McArthur, G.A., Maio, M., Arance, A., Nathan, P., Blank, C., Avril, M.-F., Garbe, C., Hauschild, A., Schadendorf, D., Hamid, O., Fluck, M., Thebeau, M., Schachter, J., Kefford, R., Chamberlain, M., Makrutzki, M., Robson, S., Gonzalez, R., Margolin, K.

“…Vemurafenib has shown activity in patients withBRAFV600 mutated melanoma with brain metastases (BM). This phase 2 study evaluated vemurafenib in patients…”
Get full text

RAS Mutations Are Associated With the Development of Cutaneous Squamous Cell Tumors in Patients Treated With RAF Inhibitors by OBERHOLZER, Patrick A, KEE, Damien, PIRIS, Adriano, MACCONAILL, Laura E, ROBERT, Caroline, HOFBAUER, Günther F. L, MCARTHUR, Grant A, SCHADENDORF, Dirk, GARRAWAY, Levi A, DZIUNYCZ, Piotr, SUCKER, Antje, KAMSUKOM, Nyam, JONES, Robert, RODEN, Christine, CHALK, Clinton J, ARDLIE, Kristin, PALESCANDOLO, Emanuele

“…RAF inhibitors are effective against melanomas with BRAF V600E mutations but may induce keratoacanthomas (KAs) and cutaneous squamous cell carcinomas (cSCCs)…”
Get full text

Checkpoint inhibitors in melanoma and early phase development in solid tumors: what's the future? by Ascierto, Paolo A, McArthur, Grant A

“…Anti-programmed death (PD)-1 and PD-ligand (L)-1 checkpoint inhibitors have revolutionized the therapy of several cancers. Immunotherapy of cancer can offer…”
Get full text

Regulation of PRMT5–MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma by AbuHammad, Shatha, Cullinane, Carleen, Martin, Claire, Bacolas, Zoe, Ward, Teresa, Chen, Huiqin, Slater, Alison, Ardley, Kerry, Kirby, Laura, Chan, Keefe T., Brajanovski, Natalie, Smith, Lorey K., Rao, Aparna D., Lelliott, Emily J., Kleinschmidt, Margarete, Vergara, Ismael A., Papenfuss, Anthony T., Lau, Peter, Ghosh, Prerana, Haupt, Sue, Haupt, Ygal, Sanij, Elaine, Poortinga, Gretchen, Pearson, Richard B., Falk, Hendrik, Curtis, David J., Stupple, Paul, Devlin, Mark, Street, Ian, Davies, Michael A., McArthur, Grant A., Sheppard, Karen E.

“…Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors are an established treatment in estrogen receptor-positive breast cancer and are currently in clinical…”
Get full text

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF -mutant melanoma by Marimuthu, Adhirai, D'Andrea, Kurt, Lin, Paul S, Puzanov, Igor, Chapman, Paul B, Zhang, Jiazhong, Tsai, James, Ibrahim, Prabha N, Cho, Hanna, West, Brian L, Nathanson, Katherine L, Zhang, Kam Y. J, Zhang, Ying, Nolop, Keith, Schlessinger, Joseph, Grippo, Joseph, Shellooe, Rafe, Zhang, Chao, Flaherty, Keith T, Tsang, Garson, Powell, Ben, Kim, Kevin B, Wong, Bernice, Stumm, Michael, Ribas, Antoni, Spevak, Wayne, Higgins, Brian, Sosman, Jeffrey A, Artis, Dean R, Habets, Gaston, Hirth, Peter, Burton, Elizabeth A, Iyer, Raman, Su, Fei, Koehler, Astrid, Lee, Richard J, Bollag, Gideon, Nguyen, Hoa, McArthur, Grant A, Xu, Xiaowei

“…B-RAF is the most frequently mutated protein kinase in human cancers. The finding that oncogenic mutations in BRAF are common in melanoma, followed by the…”
Get full text

CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer by Sanij, Elaine, Hannan, Katherine M., Xuan, Jiachen, Yan, Shunfei, Ahern, Jessica E., Trigos, Anna S., Brajanovski, Natalie, Son, Jinbae, Chan, Keefe T., Kondrashova, Olga, Lieschke, Elizabeth, Wakefield, Matthew J., Frank, Daniel, Ellis, Sarah, Cullinane, Carleen, Kang, Jian, Poortinga, Gretchen, Nag, Purba, Deans, Andrew J., Khanna, Kum Kum, Mileshkin, Linda, McArthur, Grant A., Soong, John, Berns, Els M. J. J., Hannan, Ross D., Scott, Clare L., Sheppard, Karen E., Pearson, Richard B.

“…Acquired resistance to PARP inhibitors (PARPi) is a major challenge for the clinical management of high grade serous ovarian cancer (HGSOC). Here, we…”
Get full text